Further progress has been seen for Eylea (aflibercept) biosimilars in recent days, after Formycon revealed that a European filing for its FYB203 candidate had been accepted for review by the European Medicines Agency, shortly before Alvotech unveiled positive trial results from a confirmatory clinical study for its AVT06 proposed biosimilar.
Formycon had late last year indicated that it had submitted FYB203 to the EMA, in partnership with Klinge Biopharma, the exclusive owner of the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?